McKesson Stock News

The stock price of McKesson has maintained a strong upward trend throughout multiple years because of its solid financial performance and dedicated investor support which creates a defensive investment opportunity. The company achieves strong revenue and EPS growth through its expanding oncology, biopharmaceutical and GLP-1 therapy sales, which counterbalance the typical thin margins of the sec...

The article provides a methodology for selecting high-growth dividend-paying stocks, focusing on dividend growth and sustainability rather than high current yield. We use our proprietary models to rate quantitatively and qualitatively, and select the top ten names from an initial list of nearly 400 dividend stocks. The final list of ten stocks is chosen based on sector diversity, high-growth qu...

Deal OverviewOn May 8, 2025, McKesson Corporation (NYSE: MCK, $682.28, Market Capitalization: $85.4 billion), a diversified healthcare services company, announced its intention to separate its Medical-Surgical Solutions segment into an independent company (NewCo) (for more information, visit spinoffresearch.com). McKesson is committed to exploring all opportunities to execute a separation in a ...

McKesson Corporation (NYSE:MCK ) BofA Securities 2025 Healthcare Conference May 13, 2025 11:00 AM ET Company Participants Britt Vitalone - Chief Financial Officer Conference Call Participants Allen Lutz - Bank of America Allen Lutz Welcome to day one of the BofA Healthcare Conference here in Las Vegas. We are very excited to welcome McKesson here.

Storied healthcare supplies company McKesson (MCK 0.34%) was a slight outperformer on the stock exchange Friday, as investors considered its results for its fourth quarter of fiscal 2025. They liked, if not loved, what they saw, sending the shares to a 0.5% gain on that day.

I reiterate a Strong Buy rating on McKesson Corporation with a fair value of $828 per share, driven by robust growth in the oncology and biopharma sectors. McKesson posted 19% revenue growth and 63.8% adj. EPS growth, largely driven by strong demand for GLP-1 products, which now represent 12% of total revenue. The company's global supply chain flexibility and non-discretionary drug pricing rend...

McKesson Corporation (NYSE:MCK ) Q4 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Brian Tyler - Chief Executive Officer Britt Vitalone - Chief Financial Officer Jeni Dominguez - VP of Investor Relations Conference Call Participants Kevin Caliendo - UBS Lisa Gill - JP Morgan Allen Lutz - Bank of America Eric Percher - Nephron Research Stephen Baxter - Wells Fargo Dani...

McKesson forecast fiscal 2026 profit largely above estimates on Thursday and said it is planning to spin off its medical-surgical solutions unit into an independent company to focus on its core drug distribution business.